About Bagirath
.Dr. Bagirath is a Global R&D and Translational Science Leader with over 23 years of experience spanning pharma, biotech, and academia. He has led programs advancing immune-mediated and hematologic therapies from discovery through first-in-human studies, delivering a 20+ asset pipeline, securing multimillion-dollar funding, and achieving IND approvals in record timelines.
His expertise covers biologics, gene, and cell therapies, with breakthrough contributions including high-expression FVIII molecules and novel hemophilia A gene therapies now in clinical trials. Dr. Bagirath is known for integrating AI-driven omics and biomarker platforms to accelerate translational readiness and clinical success.
As Head of Translational Research at Takeda, he directed preclinical, biomarker, and bioanalytical programs for a $6B global plasma therapies portfolio—supporting 20+ marketed products and next-generation assets across immune and rare diseases. He also chaired global steering committees and led cross-industry collaborations bridging discovery and commercialization.
Currently consulting biotech and pharma organizations across the EU, US, and India, he advises on translational strategy, AI-enabled biomarker discovery, and in-licensing for immunology, hematology, and autoimmune portfolios. His leadership consistently turns innovation into commercially viable clinical assets.
Highlights
Experienced R&D leadership
Built and led Takeda’s Translational Research & Non-Clinical Development vertical, enabling >20 marketed and pipeline products.
Fast-tracked a second-generation immunoglobulin from concept to IND in 14 months
Implemented multi-omics biomarker platforms improving patient stratification and disease insights
Ph.D. in Immunology (First Class) (Université Pierre et Marie CURIE, Paris), Grade: Highest Honors
Led scientific due diligence on 8–10 assets annually, driving in-licensing and portfolio growth.
Secured over $20M in translational grants and contributed to 30+ publications and global presentations